Study of two drugs before surgery for stage II-IIIB NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, given before surgery to shrink early-stage NSCLC (stage II to IIIB) that can be removed. The goal is to see if this approach improves outcomes compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have non-small cell lung cancer (NSCLC).
- Your cancer is stage II to IIIB and doctors believe it can be removed completely with surgery.
- You have not had any prior chemotherapy, radiation, or other cancer treatment for this lung cancer.
- Your tumor does not have certain gene mutations (EGFR or ALK).
- You are willing to undergo surgery after a few cycles of treatment with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs given before surgery to shrink tumors in people with a type of lung cancer (non-small cell) that has a specific protein called PD-L1. The goal is to see if this treatment helps remove the cancer more effectively.
This trial tests a new combination of two drugs (sacituzumab govitecan and toripalimab) given before surgery to shrink advanced oral cavity tumors. The goal is to see if this approach helps make surgery more effective and improves outcomes.
This trial tests a combination of two drugs: sacituzumab tirumotecan (SKB264) and toripalimab, for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination helps shrink or control the cancer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (Sacituzumab Govitecan and Tislelizumab) given before surgery to shrink early-stage triple-negative breast cancer. The goal is to see if a lower dose of treatment can still work well.
This study tests a combination of two immunotherapy drugs and a targeted antibody-drug before standard treatment for locally advanced cervical cancer. The goal is to see if this triple therapy can shrink tumors more effectively before surgery or radiation.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.